ReviewMolecular biology reports2025
Piezo1 in heart failure: A new perspective from cytomechanical sensing to diverse cellular pathways.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multi-omics analysis of genetic drivers linking aortic stenosis and left ventricular diastolic dysfunction in heart failure.BioData mining · 2026Article
- Role of Exercise in Modulating the Brain-Heart Axis in Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Mechanisms of the biological response cascade to exercise-induced stress: a comprehensive review.Frontiers in sports and active living · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piezo1, a mechanosensitive cation channel characterized by its distinctive transmembrane trimeric structure, plays a pivotal role in mediating cellular responses to mechanical stimuli. It facilitates calcium influx, and recent studies highlight its involvement in heart failure (HF) pathophysiology, where its dysregulation significantly contributes to disease progression. Specifically, Piezo1 upregulation impacts diverse cellular processes across cardiovascular cell types, including cardiomyocytes, fibroblasts, endothelial cells (ECs), and vascular smooth muscle cells (VSMCs). Unlike previous studies that have focused predominantly on isolated signaling pathways, this review offers a comprehensive examination of Piezo1's mechanosensory functions across diverse cardiovascular cell populations. We explored how Piezo1 modulates key pathological processes in heart failure, including calcium homeostasis, reactive oxygen species (ROS) production, fibrosis, vascular remodeling, and immune activation. Furthermore, we investigated how Piezo1-mediated interactions between different cell types, such as cardiomyocyte-fibroblast crosstalk and endothelial-smooth muscle cell interactions, serve as critical drivers of disease progression. Additionally, we discuss the therapeutic potential of targeting Piezo1, suggesting that modulating its activity may offer a novel strategy to mitigate the pathological effects of heart failure. By providing new insights into the multifaceted roles of Piezo1, this review highlights the potential of mechanosensitive ion channels as therapeutic targets for cardiovascular disease.
Indexed as
Identifiers
40900224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.